Core Viewpoint - The announcement reveals that the controlling shareholder of Berry Genomics, Mr. Gao Yang, has defaulted on a stock pledge repurchase agreement, leading to a court-ordered forced liquidation of his shares in the company [1] Group 1: Shareholder Actions - Mr. Gao Yang is subject to a court ruling that mandates the forced liquidation of up to 3.5352 million shares of Berry Genomics, which represents no more than 1% of the company's total share capital [1] - The forced execution deadline is set for July 10, 2025, indicating a timeline for the liquidation process [1] Group 2: Shareholding Changes - Following the forced execution, Mr. Gao Yang and his concerted party, Ms. Hou Ying, have seen their combined shareholding decrease from 11.99% to 11.95% of the total share capital, reflecting a change of 0.04% due to the forced execution [1] - The shares are to be executed at a price range of 12.59 to 14.84 yuan per share, which provides insight into the potential market impact of the forced sale [1]

3、公司目前生产经营情况正常，该事项未对公司正常经营活动产生重大 影响。 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-032 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人所持公司股份将被司法拍卖的 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖标的物为公司控股股东之一致行动人侯颖女士持有的本公司 13,785,075 股股票，占其持有公司股份的比例为 100.00%，占公司总股本的 比例为 3.90%。上述将被司法拍卖的股份均为无限售流通股，均已被质押并分 别被司法再冻结和司法标记。 2、目前该拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、法院执行 法定程序、股权变更、过户等环节，存在一定的不确定性，公司将根据进展情 况，依法履行相应的信息披露义务。敬请广大投资者注意投资风险。 2、股东股份累计被司法拍卖的情况 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"） 于近日收到控股股东之一致行动人侯颖女士发送的《成渝金融法院网络司法 拍卖事项通知书》并通过司法拍卖网络平台查 ...

Group 1 - The company, Chengdu Berry Genomics Technology Co., Ltd., has agreed to provide a joint liability guarantee for its wholly-owned subsidiary, Beijing Berry Genomics Biotechnology Co., Ltd., which applied for a comprehensive credit line of 30 million yuan from the Bank of China [1] - The board of directors approved the guarantee without needing to submit it to the shareholders' meeting, as per relevant regulations [1] - The total amount of external guarantees provided by the company and its subsidiaries is 317 million yuan, accounting for 18.87% of the latest audited net assets [3][4] Group 2 - The subsidiary, Beijing Berry, has total assets of approximately 2.15 billion yuan and total liabilities of about 693.94 million yuan, resulting in net assets of approximately 1.45 billion yuan [2] - The subsidiary reported a total revenue of approximately 443.45 million yuan, with a net loss of about 29.26 million yuan [2] - The company has no overdue guarantees or litigation related to guarantees as of the announcement date [4]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-031 成都市贝瑞和康基因技术股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保审批情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"） 于 2025 年 3 月 24 日召开第十届董事会第十二次会议审议通过了《关于为全资 子公司提供担保的议案》。公司之全资子公司北京贝瑞和康生物技术有限公司 （以下简称"北京贝瑞"）向中国民生银行股份有限公司北京分行（以下简称 "民生银行北京分行"）申请综合授信 10,000 万元，授信期限 1 年。公司拟为 北京贝瑞使用上述授信所形成的债务提供连带责任保证担保，北京贝瑞以取得 不动产权的位于昌平区生命园路 4 号院 5 号楼的房产为使用上述授信所形成的 债务提供抵押担保。具体内容详见公司于 2025 年 3 月 25 日在巨潮资讯网上披 露的《关于为全资子公司提供担保的公告》（公告编号：2025-007）。 近日，公司与民生银行北京分行签订了《最高额保证合同》，为北京贝瑞在 民生银行 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-029 成都市贝瑞和康基因技术股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 近日，成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基 因""公司"）之全资子公司北京贝瑞和康生物技术有限公司（以下简称"北 京贝瑞"）向中国银行北京首都机场支行申请综合授信 3,000 万元。公司同意 为北京贝瑞使用上述授信所形成的债务提供连带责任保证担保。 公司于 2025 年 6 月 4 日召开第十届董事会第十五次会议审议通过了《关于 为全资子公司提供担保的议案》。根据证监会《上市公司监管指引第 8 号—上市 公司资金往来、对外担保的监管要求》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》《公司章程》 等有关规定，本次担保无需提交股东大会审议，董事会审议通过后方可实施。 董事会授权公司总经理根据北京贝瑞实际日常经营资金需求办理担保事宜并签 署相关文件，授权有效期限与担保协议约定的保证期间一致。 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-030 成都市贝瑞和康基因技术股份有限公司 第十届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第十五次会议于2025年6月4日在北京市昌平区生命园路4号院5号楼8层会议室以 现场与通讯会议相结合的方式召开，会议通知已于2025年5月30日以邮件形式发 送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。本次董事 会会议应出席董事7名，实际出席会议董事7名，会议由董事长高扬先生主持，董 事会秘书、证券事务代表列席了会议。会议的召开和表决程序符合有关法律、行 政法规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审议通过《关于为全资子公司提供担保的议案》 表决结果：7票同意，0票反对，0票弃权。 公司全资子公司北京贝瑞和康生物技术有限公司（以下简称"北京贝瑞"） 向中国银行北京首都机场支行申请综合授信3,000万元。公司同意为北京贝瑞使 用上述授信所形成的债务提供连带 ...

Group 1 - The core viewpoint of the news is that Berry Genomics has experienced a decline in its financial performance, with significant drops in both revenue and net profit in the latest quarterly report [1] - As of the first quarter of 2025, Berry Genomics reported a revenue of 218 million yuan, representing a year-on-year decrease of 22.08% [1] - The company's net profit for the same period was a loss of approximately 6.46 million yuan, which is a year-on-year decline of 178.47% [1] Group 2 - Berry Genomics' stock closed at 15.3 yuan, marking an increase of 4.51%, with a latest price-to-book ratio of 3.24, which is the lowest in 49 days [1] - The total market capitalization of Berry Genomics is approximately 5.409 billion yuan [1] - The company has 10 institutional investors holding a total of 84.94 million shares, with a combined market value of 1.149 billion yuan [1] Group 3 - The main business of Berry Genomics focuses on high-throughput sequencing technology and related genetic testing services, including reproductive health genetic testing and hereditary disease testing for children and adults [1] - The average price-to-earnings (P/E) ratio for the industry is 50.80, while Berry Genomics has a negative P/E ratio of -26.11 [2] - The industry median price-to-book ratio is 2.48, while Berry Genomics' price-to-book ratio stands at 3.24 [2]

Company Announcements - Weir Shares plans to issue H-shares and list on the Hong Kong Stock Exchange to accelerate international strategy and enhance overseas financing capabilities [1] - Zhongjin Gold's controlling shareholder plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues [2] - Hanchuan Intelligent has filed a lawsuit against CATL and its subsidiaries for approximately 60.88 million yuan due to payment defaults [2] - Yunnan Copper intends to acquire a 40% stake in Liangshan Mining, with stock resuming trading on May 26 [3] - China Shenhua plans to acquire a 7.43% stake in China Energy Group Financial Company for 2.929 billion yuan [3] - Dike Co. intends to acquire 60% of Zhejiang Suote for 696 million yuan to control the Solamet photovoltaic silver paste business [4] - Jin Hua Co.'s chairman is under investigation for information disclosure violations, but it will not affect the company's operations [4] Financing and Investments - Heng Rui Pharmaceutical's H-shares will be listed on May 23, 2025, with a total issuance of 225 million shares at a price of 44.05 HKD per share [23] - Ningde Times' investment fund has increased to 10.128 billion yuan, with the company's stake reduced to 6.91% [8] - Intercontinental Oil and Gas expects to invest approximately 848 million USD in the Iraq South Basra project [9] - Keli Yuan plans to invest an additional 500 million yuan in a storage industry fund, increasing its total investment to 700 million yuan [10] Project Bids and Contracts - China Communications has won important rail transit projects totaling approximately 3.789 billion yuan [22] - Anhui Construction has received multiple project bids totaling over 2 billion yuan [22] Operational Updates - Zijin Mining's Kamoa-Kakula copper mine has suspended some underground mining operations due to seismic activity, potentially impacting future production [21] - Shaanxi Natural Gas will reduce pipeline transportation prices by 0.0386 yuan per cubic meter, expected to decrease net profit by approximately 222 million yuan in 2025 [20]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-028 成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东权益变动触及1%整数倍的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"） 于近日接到控股股东高扬先生所持有股份发生变动的通知，现将本次权益变动的 具体情况公告如下： 一、本次权益变动情况 | 1．基本情况 | | | --- | --- | | 信息披露义务人 | 高扬 | | 住所 | 北京市昌平区科技园区生命园路 4 号院 5 号楼 | | 权益变动时间 | 2025 年 5 月 21 日-2025 年 5 月 22 日 | | | 高扬先生因股票质押违约被质权人国信证券股份有限公 司（以下简称"国信证券"）在 2025 年 5 月 21 日-2025 | | 权益变动过程 | | | 年 | ...

Core Viewpoint - The controlling shareholder of Berry Genomics, Gao Yang, has been forced to reduce his stake in the company by 0.38% due to a stock pledge default, resulting in the forced sale of 1,331,583 shares by the creditor, Guosen Securities, between May 21 and May 22, 2025 [1]. Company Summary - Berry Genomics received a notification from its controlling shareholder, Gao Yang, regarding a stock pledge default [1]. - The forced sale involved 1,331,583 shares, which represents 0.38% of the company's total share capital [1].